IBRX ImmunityBio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IBRX

Price (delayed)

$8.63

Market cap

$9.15B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.97

Enterprise value

$10.3B

?
Relative Growth: Rel. Growth: 57
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 18

ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company’s range of immunotherapy platforms, alone ...

Highlights
ImmunityBio's revenue has surged by 193% YoY and by 18% QoQ
The company's gross profit has surged by 192% YoY and by 18% QoQ
ImmunityBio's quick ratio has soared by 54% YoY but it has decreased by 14% from the previous quarter
ImmunityBio's net income has shrunk by 170% YoY and by 16% QoQ
ImmunityBio's EPS has shrunk by 120% YoY and by 14% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of IBRX

IBRX stock price

How has the ImmunityBio stock price performed over time
Intraday
-7.1%
1 week
9.1%
1 month
10.78%
1 year
233.2%
YTD
335.86%
QTD
-1.43%

Financial performance

How have ImmunityBio's revenue and profit performed over time
Revenue
$165.79M
Gross profit
$164.7M
Operating income
-$251.8M
Net income
-$992.36M
Gross margin
99.3%
Net margin
-598.6%
ImmunityBio's revenue has surged by 193% YoY and by 18% QoQ
The company's gross profit has surged by 192% YoY and by 18% QoQ
ImmunityBio's net income has shrunk by 170% YoY and by 16% QoQ
ImmunityBio's operating margin has soared by 70% YoY and by 18% from the previous quarter

Price vs fundamentals

How does IBRX's price correlate with its fundamentals

Growth

What is ImmunityBio's growth rate over time

Valuation

What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
54.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62.12
ImmunityBio's EPS has shrunk by 120% YoY and by 14% QoQ
ImmunityBio's equity has shrunk by 83% YoY and by 20% QoQ
ImmunityBio's revenue has surged by 193% YoY and by 18% QoQ
The P/S is 98% less than the 5-year quarterly average of 2744.9 but 51% more than the last 4 quarters average of 38.9

Efficiency

How efficient is ImmunityBio business performance
The company's return on invested capital has shrunk by 184% YoY and by 4.5% QoQ
IBRX's return on assets has dropped by 71% year-on-year and by 4.7% since the previous quarter
ImmunityBio's return on sales has decreased by 29% YoY

Dividends

What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBRX.

Financial health

How did ImmunityBio financials performed over time
The total assets is 62% less than the total liabilities
ImmunityBio's total liabilities has soared by 72% YoY and by 10% from the previous quarter
The total assets has soared by 56% YoY but it has contracted by 2.8% from the previous quarter
ImmunityBio's equity has shrunk by 83% YoY and by 20% QoQ
The debt rose by 46% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.